| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5312925 | VIATRIS | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(11 years ago) | |
| US6245766 | VIATRIS | Method of treating psychiatric conditions |
Dec, 2018
(5 years ago) | |
| US6150366 | VIATRIS | Ziprasidone formulations |
May, 2019
(4 years ago) | |
Geodon is owned by Viatris.
Geodon contains Ziprasidone Hydrochloride.
Geodon has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Geodon are:
- US5312925
- US6245766
- US6150366
Geodon was authorised for market use on 05 February, 2001.
Geodon is available in capsule;oral dosage forms.
Geodon can be used as treatment of bipolar disorder.
The generics of Geodon are possible to be released after 28 January, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-232) | Jan 28, 2025 |
| New Indication(I-615) | Nov 20, 2012 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 February, 2001
Treatment: Treatment of bipolar disorder
Dosage: CAPSULE;ORAL
GEODON family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5312925 | PFIZER INC | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(11 years ago) | |
| US6245766 | PFIZER INC | Method of treating psychiatric conditions |
Dec, 2018
(5 years ago) | |
| US6150366 | PFIZER INC | Ziprasidone formulations |
May, 2019
(4 years ago) | |
| US7175855 | PFIZER INC | Ziprasidone suspension |
May, 2020
(3 years ago) | |
Geodon is owned by Pfizer Inc.
Geodon contains Ziprasidone Hydrochloride.
Geodon has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Geodon are:
- US5312925
- US6245766
- US6150366
- US7175855
Geodon was authorised for market use on 29 March, 2006.
Geodon is available in suspension;oral dosage forms.
Geodon can be used as treatment of bipolar disorder, treatment of psychosis, treatment of neuroleptic diseases.
The generics of Geodon are possible to be released after 18 May, 2020.
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 March, 2006
Treatment: Treatment of neuroleptic diseases; Treatment of bipolar disorder; Treatment of psychosis
Dosage: SUSPENSION;ORAL
GEODON family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6110918 | VIATRIS | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar, 2017
(7 years ago) | |
| US6399777 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(7 years ago) | |
| US6232304 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(7 years ago) | |
Geodon is owned by Viatris.
Geodon contains Ziprasidone Mesylate.
Geodon has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Geodon are:
- US6110918
- US6399777
- US6232304
Geodon was authorised for market use on 21 June, 2002.
Geodon is available in powder;intramuscular dosage forms.
The generics of Geodon are possible to be released after 01 April, 2017.
Drugs and Companies using ZIPRASIDONE MESYLATE ingredient
Market Authorisation Date: 21 June, 2002
Treatment: NA
Dosage: POWDER;INTRAMUSCULAR
GEODON family patents